Transition to multicomponent preventive drugs is necessary

Print 25 September 2017
GMP News

During the second BIOTECHMED conference held in Gelendzhik, the representatives of Nacimbio, a company which is part of Rostec Corporation, participated in panel discussions on preventive vaccination and expansion of the National Immunization Calendar.

The discussions were specially focused on the need for transition to multicomponent preventive drugs.

“Today, a child with 2-3 indications for immunization, can receive up to 10 injections. If we plan to expand the National Calendar, first of all, we need to work on advanced multicomponent drugs.  Only the transition from mono- to polycomponent vaccines will allow to reduce the injection load and get a “window” for further expanding the list of National Immunization Calendar,” said Anton Katlinsky, the President of FORT, a biopharmaceutical company.

Following the global trends, the companies that are part of the Nacimbio perimeter have been actively working on new combination drugs for several years already.

“The transition to polyvaccines is the matter that requires a comprehensive solution. Even today, we already see the positive dynamics: a four-component DTP-HepB vaccine was included in the National Immunization Calendar; and we have submitted documents for the registration of five-component DTP-HepB+Hib vaccine with whole-cell and acellular pertussis components,” said Kirill Gaidash, the acting General Director of NPO Microgen. “Another example is MMR (measles, mumps, rubella) vaccine, which we plan to register by 2018 and propose it to the Russian Ministry of Health for inclusion in the National Calendar.”

Source

Return